Institut Gustave Roussy

Type: Organization

Name: Institut Gustave Roussy

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Sharjah’s high tech breast cancer centre ready to get to work

The centre at Sharjah University Hospital is a joint co-operation with The Institut Gustave Roussy in France. ... [Published Abu Dhabi National - May 09 2013]

Entities: Sharjah, Breast Cancer, Institut Gustave Roussy

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Study Published in Journal of Clinical Oncology Finds High Concordance of Genomic Alterations in NSCLC Business Wire

CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)-- Foundation Medicine, Inc. and the Institut Gustave Roussy today announced the results of a next-generation sequencing study of primary and matched metastatic tumor pairs from 15 patients with non-small cell ... [Published Yahoo! Finance - Apr 30 2013]

Entities: Foundation Medicine Inc, Genomics, non-small cell lung cancer

First reported Apr 20 2013 - Updated Apr 21 2013 - 1 reports

Study reveals that chemotherapy works in an unexpected way

(NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- It's generally thought that anticancer chemotherapies work like antibiotics do, by directly killing off what's harmful. But new research published online on April 4 in the Cell Press ... [Published NewsRX - Apr 20 2013]

Entities: Chemotherapy, Tumor, Cancer

Quotes

"The results of this study generated hypotheses for developing more rational targeted therapy combinations based on the specific genetic aberrations present in each individual tumour" Dr Piccart said

Study opens new prospects for developing new targeted therapies for breast cancer [Published EurekAlert! - May 02 2013]

...profiling in some settings," said Vincent Miller, senior vice president of clinical development at Foundation Medicine, and co-author of the study. "While additional research is needed and these results cannot be generalized to other settings, this is a promising result for patients as these samples are often available for analysis without the need for an invasive re-biopsy solely for genotyping."

Study Published in Journal of Clinical Oncology Finds High Concordance of Genomic Alterations in ... [Published NewsBlaze - Apr 30 2013]

"Successful chemotherapeutics convert the tumor into a therapeutic vaccine, hence mobilizing the host's immune system against the cancer" explains senior author Dr. Guido Kroemer, of the Institut Gustave Roussy, in France

Study reveals that chemotherapy works in an unexpected way [Published NewsRX - Apr 20 2013]

"Ion AmpliSeq™ technology has allowed us to substantially improve the turnaround time and cost of sequencing these important genes," said Costa. "The methodology proved robust enough to call even difficult mutations, including long homopolymers, in these two genes."

Life Technologies Launches Two Ion AmpliSeq™ Community Panel Designs: Ion AmpliSeq™ BRCA1 and BRC ... [Published Yahoo! Finance - Apr 02 2013]

More Content

sort by: Date \| Relevance
KOL Insight: Prostate Cancer: Competition inten... [Published PipelineReview - May 20 2013]
Clarifying misconceptions about palm oil [Published thestar.com.my - May 12 2013]
Sharjah’s high tech breast cancer centre ready ... [Published Abu Dhabi National - May 09 2013]
QIAGEN Marseille (Alternext - FR0010626028 - AL... [Published MoneyAM - May 06 2013]
Study opens new prospects for developing new ta... [Published EurekAlert! - May 02 2013]
Study Published in Journal of Clinical Oncology... [Published Yahoo! Finance - Apr 30 2013]
Study Published in Journal of Clinical Oncology... [Published NewsBlaze - Apr 30 2013]
Study reveals that chemotherapy works in an une... [Published NewsRX - Apr 20 2013]
Life Technologies Launches Two Ion AmpliSeq™ Co... [Published Yahoo! Finance - Apr 02 2013]
EU grants conditional marketing nod to Pfizerâs... [Published PharmaBiz - Oct 25 2012]
Ipsen, Active Biotech begin phase II proof of c... [Published PharmaBiz - Oct 05 2012]
Pfizer's Inlyta receives European marketing app... [Published PharmaBiz - Sep 05 2012]